$CLX earnings report

Clorox Reports Q1 Fiscal Year 2027 Results, Updates Outlook. AlphAI read Clorox's Q1 fiscal year 2027 filing as mixed. 2 quarters are on record below.

Q1 fiscal year 2027

AlphAI · Earnings readCLX · Q1 fiscal year 2027 · ended Sept. 30, 2026

Clorox Reports Q1 Fiscal Year 2027 Results, Updates Outlook

→Mixed quarter

Net sales increased 33% and adjusted EPS increased 82%, supported by GOJO, volume, cost savings and lapping the ERP-related inventory drawdown. Gross margin declined 130 basis points amid higher commodity, manufacturing and logistics costs, and the company expects adjusted EPS closer to the low end of its maintained fiscal year 2027 range.

Revenue
$1.91B
33 % y/y
Health and Wellness
$918M
62 % y/y
Gross margin · GAAP
40.4%
decreased 130 basis points y/y
EPS · non-GAAP
$ 1.55
82 % y/y
Fiscal year 2027 full year outlook outlook
Net sales are still expected to be up 13% to 14% compared to the prior year, including about 9.5 points of benefit from the GOJO acquisition. Organic sales are expected to increase about 3.5% to 4.5%, including more than 3.5 points of benefit from lapping the ERP-related drawdown in the prior fiscal year.
GM about 41.5%

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Net salesGAAP$1.91B–33 %
Organic sales growth / (decrease)non-GAAP18 %–18 %
Cost of products soldGAAP$1.14B––
Gross profitGAAP$770M––
Gross marginGAAP40.4%–decreased 130 basis points
Adjusted gross profitnon-GAAP780––
Adjusted gross marginnon-GAAP40.9 %––
Selling and administrative expensesGAAP$290M––
Selling and administrative expenses as a percent of net salesGAAP15.2 %––
Adjusted selling and administrative expensesnon-GAAP274––
Adjusted selling and administrative expenses as a percent of net salesnon-GAAP14.4 %––
Advertising costsGAAP190––
Research and development costsGAAP29––
Interest expenseGAAP52––
Other (income) expense, netGAAP2––
Earnings before income taxesGAAP$207M–93 %
Adjusted EBITnon-GAAP$284M––
Income tax expenseGAAP34––
Net earningsGAAP173––
Net earnings attributable to CloroxGAAP$170M––
Adjusted net earnings attributable to Cloroxnon-GAAP190––
Basic net earnings per shareGAAP$ 1.39––
Diluted net earnings per shareGAAP$ 1.39–114 %
Adjusted diluted earnings per sharenon-GAAP$ 1.55–82 %
Weighted average shares outstanding, basicGAAP121,619––
Weighted average shares outstanding, dilutedGAAP122,027––
Year-to-date net cash provided by operationsGAAP$143M–54% increase
Health and Wellness segment adjusted EBITnon-GAAP$209M–69 %
Household segment adjusted EBITnon-GAAP30–11 %
Lifestyle segment adjusted EBITnon-GAAP60–58 %
International segment adjusted EBITnon-GAAP31–63 %

Segments

SegmentRevenueq/qy/y
Health and WellnessHigher volume contributed 55 points and favorable price mix contributed 7 points. The GOJO acquisition contributed approximately 39 points to net sales growth.$918M–62 %
HouseholdGrowth was driven by 17 points of higher volume, primarily from lapping the ERP transition-related inventory drawdown in the year-ago quarter.423M–17 %
LifestyleGrowth was driven by 15 points of higher volume and 1 point of favorable price mix. Volume benefited from lapping the ERP transition-related inventory drawdown.283M–16 %
InternationalOrganic sales increased 9%, driven by 9 points of organic volume growth, supported by strong shipments across several regions, particularly in Latin America.281M–11 %

Amounts quoted below without a unit are in millions, as in the filing’s tables. Per-share figures are as printed.

Fiscal year 2027 full year outlook outlook

  • RevenueNet sales are still expected to be up 13% to 14% compared to the prior year, including about 9.5 points of benefit from the GOJO acquisition. Organic sales are expected to increase about 3.5% to 4.5%, including more than 3.5 points of benefit from lapping the ERP-related drawdown in the prior fiscal year.
  • Gross marginabout 41.5%
  • Operating expensesSelling and administrative expenses are now expected to be about 15.5% of net sales. Advertising and sales promotion spending is still expected to be about 10% of net sales. This assumes about 12% of net sales for its retail businesses.
  • Tax rateabout 23%
  • NoteDiluted EPS is still expected to be between $5.41 and $5.71, a year-over-year increase of 12% to 19%, respectively.
  • NoteAdjusted EPS is still expected to be between $5.70 and $6.00, or an increase between 3% and 8%, respectively.
  • NoteDiluted EPS includes about 29 cents of impact from transaction-related costs associated with the GOJO acquisition.
  • NoteGross margin includes about 20 basis points of negative impact primarily related to the GOJO inventory step-up.
  • NoteSelling and administrative expenses include about 40 basis points of negative impact from GOJO transaction-related costs.
  • NoteThe company expects adjusted EPS results closer to the low end of the range.

What drove it

  • Total net sales growth was driven by 31 points of higher volume and 2 points of favorable price mix.
  • The GOJO acquisition contributed 15 points to total net sales growth.
  • Organic sales growth reflected about 18 points of benefit from lapping the ERP transition-related inventory drawdown in the year-ago quarter.
  • Adjusted EPS growth was driven by higher net sales, cost savings and a lower tax rate.
  • The company delivered one of the strongest quarters of cost savings on record.
  • Clorox officially launched Clorox Purell ProCare, combining CloroxPro and GOJO under a unified sales and service organization.

Concerns

  • Gross margin decreased 130 basis points, primarily due to higher commodity costs and higher manufacturing and logistics costs.
  • The impact from inventory step-up of the GOJO acquisition was about 50 basis points to first-quarter gross margin.
  • The cost environment has become more challenging, with higher inflationary pressures reflected in the updated outlook.
  • Fiscal year 2027 gross margin is expected to reflect higher-than-normal inflationary headwinds and negative mix more than offsetting cost savings and pricing actions.
  • GOJO transaction-related costs are expected to affect cost of goods sold and selling and administrative expenses.
  • The reported growth rate benefited from lapping the ERP transition-related inventory drawdown in the year-ago quarter.

What to watch

  • Progress in mitigating higher commodity, manufacturing and logistics costs.
  • Whether adjusted EPS trends toward the low end of the maintained $5.70 to $6.00 outlook range.
  • Realization of GOJO acquisition synergies and integration of Clorox Purell ProCare.
  • The effect of negative mix and GOJO inventory step-up on gross margin.
  • The durability of volume growth after the benefit from lapping the ERP transition-related inventory drawdown.

Balance sheet and cash flow

  • Cash and cash equivalents were $ 184 at 9/30/2026, compared with $ 143 at 6/30/2026 and $ 166 at 9/30/2025.
  • Notes and loans payable were $ 1,175 at 9/30/2026, compared with $ 1,086 at 6/30/2026 and $ 218 at 9/30/2025.
  • Current maturities of long-term debt were 1 at 9/30/2026, 1 at 6/30/2026 and — at 9/30/2025.
  • Long-term debt was 3,982 at 9/30/2026, compared with 3,981 at 6/30/2026 and 2,485 at 9/30/2025.
  • Year-to-date net cash provided by operations was $143 million compared to $93 million in the year-ago period, representing a 54% increase.

Analysis

Clorox opened fiscal year 2027 with a sharp recovery in reported sales and earnings. Net sales increased 33% to $ 1,905, while organic sales growth was 18%. Total growth reflected 31 points of higher volume and 2 points of favorable price mix, with the GOJO acquisition contributing 15 points. The reported organic growth rate also reflected about 18 points of benefit from lapping the ERP transition-related inventory drawdown in the year-ago quarter, making that comparison a central consideration in assessing underlying demand momentum.

Management, verbatim

We entered this fiscal year focused on steadily improving performance while navigating continued input cost pressures. We made good progress in the first quarter, delivering better-than-expected results through strong execution and timing benefits.

Linda Rendle, Chair and CEO

The cost environment has become more challenging, with higher inflationary pressures reflected in our updated outlook. We have plans in place to mitigate these pressures while continuing to invest behind our brands.

Linda Rendle, Chair and CEO

Not in the filing

stated, not guessed
  • Operating income
  • Operating margin
  • Free cash flow
  • Cash flow from investing activities
  • Cash flow from financing activities
  • Capital expenditures
  • Share repurchases
  • Dividends
  • Prior-quarter comparisons for reported quarterly metrics
  • Prior-year adjusted gross margin
  • Prior-year adjusted selling and administrative expenses
  • Prior-year adjusted net earnings attributable to Clorox

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Q4 and fiscal year 2026

AlphAI · Earnings readCLX · Q4 and fiscal year 2026 · ended June 30, 2026

Clorox Reports Q4 and FY26 Results, Provides FY27 Outlook

→Mixed quarter

Fourth-quarter net sales, gross margin, diluted EPS and adjusted EPS declined, primarily reflecting ERP-related shipment comparisons, while Health and Wellness net sales grew and fiscal year 2027 guidance calls for net sales growth and higher diluted EPS.

Revenue
$1.95B
decreased 2% y/y
Health and Wellness (Cleaning; Professional Products, now including Clorox Purell)
Net sales increased 16%
increased 16% y/y
Gross margin · GAAP
41.3%
decreased 520 basis points y/y
EPS · GAAP
$1.34
decreased 50% y/y
Fiscal year 2027 outlook
Net sales are expected to be up 13% to 14% compared to the prior year, including about 9.5 points of benefit from the GOJO acquisition.
GM about 42%

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Fourth-quarter net salesGAAP$1.95B–decreased 2%
Fourth-quarter organic salesnon-GAAPdecreased 13%–decreased 13%
Fourth-quarter gross marginGAAP41.3%–decreased 520 basis points
Fourth-quarter diluted net earnings per shareGAAP$1.34–decreased 50%
Fourth-quarter adjusted EPSnon-GAAP$1.66–decreased 42%
Fiscal year 2026 net salesGAAP$6.72B–decreased 5%
Fiscal year 2026 organic salesnon-GAAPdecreased 8%–decreased 8%
Fiscal year 2026 gross marginGAAP42.3%–decreased 290 basis points
Fiscal year 2026 diluted EPSGAAP$4.81–decreased 26%
Fiscal year 2026 adjusted EPSnon-GAAP$5.53–decreased 28%
Fiscal year 2026 net cash provided by operationsGAAP$612M–38% decrease
Health and Wellness segment adjusted EBITnon-GAAPdecreased 15%–decreased 15%
Household segment adjusted EBITnon-GAAPdecreased 56%–decreased 56%
Lifestyle segment adjusted EBITnon-GAAPdecreased 60%–decreased 60%
International segment adjusted EBITnon-GAAPincreased 17%–increased 17%

Segments

SegmentRevenueq/qy/y
Health and Wellness (Cleaning; Professional Products, now including Clorox Purell)Driven by 10 points of higher volume and 6 points of favorable price mix. The GOJO acquisition contributed approximately 28 points to net sales growth. Organic sales declined 12%, primarily driven by the impact of lapping the incremental shipments related to the ERP transition in the year-ago quarter.Net sales increased 16%–increased 16%
Household (Bags and Wraps; Cat Litter; Grilling)Driven by 16 points of lower volume and 2 points of unfavorable price mix. The volume decrease is primarily due to the impact of lapping the incremental shipments related to the ERP transition in the year-ago quarter and shipment ahead of consumption in the third quarter.Net sales decreased 18%–decreased 18%
Lifestyle (Food; Water Filtration; Natural Personal Care)Driven by 14 points of lower volume and 3 points of unfavorable price mix. The volume decrease is primarily due to the impact of lapping the incremental shipments related to the ERP transition in the year-ago quarter.Net sales decreased 17%–decreased 17%
International (Sales Outside the U.S.)Primarily driven by favorable foreign exchange rates. Organic sales grew 1%.Net sales increased 4%–increased 4%

Fiscal year 2027 outlook

  • RevenueNet sales are expected to be up 13% to 14% compared to the prior year, including about 9.5 points of benefit from the GOJO acquisition.
  • Gross marginabout 42%
  • Operating expensesSelling and administrative expenses are expected to be about 16% of net sales. Advertising and sales promotion spending is expected to be about 10% of net sales.
  • Tax rateabout 23%
  • NoteOrganic sales are expected to increase about 3.5% to 4.5%, including more than 3.5 points of benefit from lapping the ERP-related drawdown in the prior fiscal year.
  • NoteGross margin includes about 20 basis points of negative impact primarily related to the GOJO inventory step-up.
  • NoteSelling and administrative expenses include about 40 basis points of negative impact from GOJO transaction-related costs.
  • NoteAdvertising and sales promotion spending assumes over 11% of net sales for its retail businesses.
  • NoteDiluted EPS is expected to be between $5.41 and $5.71, a year-over-year increase of 12% to 19%, respectively.
  • NoteDiluted EPS includes about 29 cents of impact from transaction-related costs associated with the GOJO acquisition, which are expected to flow through cost of goods sold as well as selling and administrative expenses.

What drove it

  • The GOJO acquisition added about 10 points to fourth-quarter net sales and about 3 points to fiscal year 2026 net sales.
  • Fourth-quarter organic sales decreased 13%, primarily due to lapping the incremental shipments related to the ERP transition, which is about 13.5 points.
  • Fiscal year 2026 organic sales decreased 8%, mainly due to lapping incremental shipments related to the ERP transition in the fourth quarter, which is about 7.5 points.
  • Fourth-quarter gross margin was affected by lower volume, the impact from the inventory step-up of the GOJO acquisition, higher commodity costs and higher manufacturing and logistics costs, partially offset by cost savings.
  • The company completed the acquisition of GOJO in April 2026 and completed its U.S. ERP implementation.
  • Clorox’s global health and hygiene portfolio now represents more than half of net sales.

Concerns

  • Fourth-quarter gross margin decreased 520 basis points to 41.3% from 46.5%.
  • Fiscal year 2026 gross margin decreased 290 basis points to 42.3% from 45.2%.
  • Household net sales decreased 18% and Lifestyle net sales decreased 17%.
  • The fiscal year 2027 outlook assumes higher-than-normal inflationary headwinds and negative mix.
  • The company expects the operating environment to remain challenging, with continued cost volatility and a value-seeking consumer.

What to watch

  • Whether organic sales increase about 3.5% to 4.5% in fiscal year 2027.
  • The expected more than 3.5 points of benefit to net sales growth from lapping the ERP-related drawdown.
  • The approximately 9.5 points of expected benefit from the GOJO acquisition to fiscal year 2027 net sales growth.
  • Gross margin expected to be about 42%, including about 20 basis points of negative impact primarily related to the GOJO inventory step-up.
  • Selling and administrative expenses expected to include about 40 basis points of negative impact from GOJO transaction-related costs.

Balance sheet and cash flow

  • Net cash provided by operations was $612 million compared to $981 million in fiscal year 2025, representing a 38% decrease.
  • The decrease was primarily driven by the Glad Venture Agreement termination payment.

Analysis

Clorox closed fiscal year 2026 with a weak fourth-quarter comparison. Net sales decreased 2% to $1.95 billion, organic sales decreased 13%, gross margin decreased 520 basis points to 41.3%, diluted net earnings per share decreased 50% to $1.34, and adjusted EPS decreased 42% to $1.66. The company identified the ERP-related shipment comparison as about 13.5 points of the organic-sales decline and about 90 cents of the adjusted-EPS impact.

The sales mix across segments was uneven. Health and Wellness net sales increased 16%, supported by 10 points of higher volume, 6 points of favorable price mix and approximately 28 points from GOJO. In contrast, Household net sales decreased 18% and Lifestyle net sales decreased 17%, with each affected by lapping incremental ERP-transition shipments. International net sales increased 4%, primarily driven by favorable foreign exchange rates, while organic sales grew 1%.

Full-year results similarly reflected the ERP comparison and expense pressures. Fiscal year 2026 net sales decreased 5% to $6.72 billion and organic sales decreased 8%. Gross margin decreased 290 basis points to 42.3%, while diluted EPS decreased 26% to $4.81 and adjusted EPS decreased 28% to $5.53. The company cited lower net sales and higher manufacturing and logistics costs, partly offset by cost savings, and said GOJO transaction-related costs negatively affected gross margin by about 50 basis points.

Cash generation declined during the year. Net cash provided by operations was $612 million compared to $981 million in fiscal year 2025, with the decrease primarily driven by the Glad Venture Agreement termination payment. The company also completed the GOJO acquisition and its U.S. ERP implementation, while implementing a simplified operating structure.

Fiscal year 2027 guidance calls for net sales growth of 13% to 14%, including about 9.5 points from GOJO, and organic sales growth of about 3.5% to 4.5%. The outlook embeds more than 3.5 points of benefit from lapping the ERP-related drawdown, but also assumes higher-than-normal inflationary headwinds, negative mix and GOJO transaction-related costs. Gross margin is expected to be about 42%, and diluted EPS is expected to be between $5.41 and $5.71.

Management, verbatim

Our fourth-quarter results were in line with our expectations and reflect disciplined execution in a dynamic environment.

Linda Rendle, Chair and CEO

As we begin fiscal year 2027, we expect the operating environment to remain challenging, with continued cost volatility and a value-seeking consumer.

Linda Rendle, Chair and CEO

We are confident that the investments we've made in our brands, capabilities and products position us to deliver long-term value for shareholders.

Linda Rendle, Chair and CEO

Not in the filing

stated, not guessed
  • Fourth-quarter GAAP net income.
  • Fiscal year 2026 GAAP net income.
  • Fourth-quarter operating income.
  • Fiscal year 2026 operating income.
  • Fourth-quarter operating cash flow.
  • Free cash flow.
  • Cash balance.
  • Debt balance.
  • Share repurchases.
  • Dividends.
  • Dollar revenue for each reportable segment.
  • Prior-quarter comparisons for reported metrics.
  • Previous-release outlook for comparison with actual results.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about CLX earnings dates

When is Clorox's next earnings date?
AlphAI has no date for CLX yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.